SSRI vs NDRI: Which Is Better for Post-Stroke Depression?
A recent study has compared the effectiveness of fluoxetine and bupropion for treating post-stroke depression. Bupropion showed a lower risk of suicidal ideation, while fluoxetine was more effective in reducing demoralization and apathy. The findings emphasize the need for personalized treatment approaches based on individual symptoms.
- ▪Bupropion was associated with a significantly lower risk for suicidal ideation compared to fluoxetine.
- ▪Fluoxetine was more effective in decreasing demoralization and apathy than bupropion.
- ▪The study included data from over 100,000 patients diagnosed with post-stroke depression.
Opening excerpt (first ~120 words) tap to expand
SAN FRANCISCO — The selective serotonin reuptake inhibitor (SSRI) fluoxetine and the norepinephrine-dopamine reuptake inhibitor (NDRI) bupropion are each effective for different psychiatric symptoms of post-stroke depression (PSD), new research suggests. In a large retrospective cohort study with data for more than 100,000 patients with PSD, bupropion was associated with a significantly lower risk for suicidal ideation — the primary outcome — compared to treatment with fluoxetine.However, for the secondary outcome of decreased demoralization and apathy, fluoxetine was the winner. The results highlight the importance of customizing PSD treatment to the patient, said investigator Jaime Villa, an incoming first-year medical student at Reading Hospital, Tower Health System.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
